Editorial: What is peripheral spondyloarthritis?

Arthritis and Rheumatology

Volumn 67, Issue 4, 2015, Pages 865-868

  Gladman, Dafna D ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; C REACTIVE PROTEIN; CERTOLIZUMAB PEGOL; ETANERCEPT; HLA B27 ANTIGEN; METHOTREXATE; SALAZOSULFAPYRIDINE; ANTIRHEUMATIC AGENT; MONOCLONAL ANTIBODY;

ANKYLOSING SPONDYLITIS; ANKYLOSING SPONDYLITIS DISEASE ACTIVITY SCORE; ARTHRITIS; BACKACHE; BATH ANKYLOSING SPONDYLITIS DISEASE ACTIVITY INDEX; CLINICAL FEATURE; CONSTRUCT VALIDITY; CROHN DISEASE; DACTYLITIS; DEFORMITY; DISABILITY; DISEASE ACTIVITY; DISEASE CLASSIFICATION; DRUG EFFICACY; ENTHESITIS; FAMILY HISTORY; HEALTH ASSESSMENT QUESTIONNAIRE; HUMAN; PERIPHERAL SPONDYLOARTHRITIS; PHENOTYPE; PRIORITY JOURNAL; PSORIASIS; PSORIATIC ARTHRITIS; REACTIVE ARTHRITIS; REVIEW; RHEUMATOID ARTHRITIS; SACROILIITIS; SENSITIVITY AND SPECIFICITY; SHORT FORM 36; SPONDYLARTHRITIS; TEST RETEST RELIABILITY; TREATMENT RESPONSE; ULCERATIVE COLITIS; UVEITIS; FEMALE; MALE;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; FEMALE; HUMANS; MALE; SPONDYLARTHRITIS;

EID: 84925778140     PISSN: 23265191     EISSN: 23265205     Source Type: Journal    
DOI: 10.1002/art.39014     Document Type: Review

References (10)

1. Wright V, Moll JM, editors. Seronegative spondyloarthritis. Amsterdam: North Holland Publishing; 1976.
2. Dougados M, van der Linden S, Juhlin R, Huitfeldt B, Amor B, Calin A, et al, and the European Spondylarthropathy Study Group. The European Spondylarthropathy Study Group preliminary criteria for the classification of spondylarthropathy. Arthritis Rheum 1991; 34: 1218-27.
3. Rudwaleit M, van der Heijde D, Landewe R, Akkoc N, Brandt J, Chou CT, et al. The Assessment of SpondyloArthritis international Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general. Ann Rheum Dis 2011; 70: 25-31.
4. Robinson PC, Wordsworth BP, Reveille JD, Brown MA,. Axial spondyloarthritis: a new disease entity, not necessarily early ankylosing spondylitis. Ann Rheum Dis 2013; 72: 162-5.
5. Sieper J, van der Heijde D, Dougados M, Mease PJ, Maksymowych WP, Brown MA, et al. Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: results of a randomised placebo-controlled trial (ABILITY-1). Ann Rheum Dis 2013; 72: 815-22.
6. Landewe R, Braun J, Deodhar A, Dougados M, Maksymowych WP, Mease PJ, et al. Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled phase 3 study. Ann Rheum Dis 2014; 73: 39-47.
7. Dougados M, van der Heijde D, Sieper J, Braun J, Maksymowych WP, Citera G, et al. Symptomatic efficacy of etanercept and its effects on objective signs of inflammation in early nonradiographic axial spondyloarthritis: a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheumatol 2014; 66: 2091-102.
8. Van den Berg R, van Gaalen F, van der Helm-van Mil A, Huizinga T, van der Heijde D,. Performance of classification criteria for peripheral spondyloarthritis and psoriatic arthritis in the Leiden Early Arthritis cohort. Ann Rheum Dis 2012; 71: 1366-9.
9. Mease P, Sieper J, van den Bosch F, Rahman P, Karunaratne PM, Pangan AL,. Randomized controlled trial of adalimumab in patients with nonpsoriatic peripheral spondyloarthritis. Arthritis Rheumatol 2015; 67: 914-23.
10. Clegg DO, Reda DJ, Mejias E, Cannon GW, Weisman MH, Taylor T, et al. Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis: a Department of Veterans Affairs Cooperative Study. Arthritis Rheum 1996; 39: 2013-20.